Guardant Health Inc. (GH)
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.48 per share a year ago.
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript
Guardant Health, Inc. (NASDAQ:GH ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Tycho Peterson - Jefferies Bill Bonello - Craig-Hallum Subbu Nambi - Guggenheim Partners Puneet Souda - Leerink Partners Dan Leonard - UBS Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Operator Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings Call. My name is Elliot, and I will be your coordinator today.
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.46 per share a year ago.
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently generating record revenues and growth for GH. Similarly, GH has an expanding pipeline, which includes its Reveal and Shield tests, that could significantly boost its future market potential.
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CRC) screening.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents.
Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Patrick Donnelly - Citi Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JPMorgan Kyle Mikson - Canaccord Mason Carrico - Stephens Inc. Matt Sykes - Goldman Sachs Operator Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call.
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.58 per share a year ago.
Guardant Health Tops Q4 Revenue Forecast
Guardant Health (GH -3.26%), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts' consensus estimates of $192 million.
